Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Free Cash Flow (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Free Cash Flow for 13 consecutive years, with -$133.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Free Cash Flow fell 25.6% to -$133.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$190.0 million, a 58.42% increase, with the full-year FY2025 number at -$190.0 million, up 58.42% from a year prior.
  • Free Cash Flow was -$133.1 million for Q4 2025 at Madrigal Pharmaceuticals, down from $79.0 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $79.0 million in Q3 2025 to a low of -$149.5 million in Q1 2024.
  • A 5-year average of -$69.1 million and a median of -$62.8 million in 2022 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: plummeted 93.21% in 2021, then soared 218.79% in 2025.
  • Madrigal Pharmaceuticals' Free Cash Flow stood at -$48.2 million in 2021, then fell by 21.55% to -$58.5 million in 2022, then crashed by 38.3% to -$81.0 million in 2023, then crashed by 30.85% to -$105.9 million in 2024, then decreased by 25.6% to -$133.1 million in 2025.
  • Per Business Quant, the three most recent readings for MDGL's Free Cash Flow are -$133.1 million (Q4 2025), $79.0 million (Q3 2025), and -$47.1 million (Q2 2025).